A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is an single-arm, Phase II multi-center study. The purpose of this study is to assess
the efficacy and safety of Jaktinib in subjects with Grades II to IV steroid-refractory acute
graft-versus-host disease.